TY - JOUR
T1 - STI571
T2 - a gene product-targeted therapy for leukemia.
AU - Mauro, M. J.
AU - Druker, B. J.
PY - 2001/5
Y1 - 2001/5
N2 - Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.
AB - Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.
UR - http://www.scopus.com/inward/record.url?scp=0035344667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035344667&partnerID=8YFLogxK
U2 - 10.1007/s11912-001-0054-z
DO - 10.1007/s11912-001-0054-z
M3 - Review article
C2 - 11296132
AN - SCOPUS:0035344667
SN - 1523-3790
VL - 3
SP - 223
EP - 227
JO - Current oncology reports
JF - Current oncology reports
IS - 3
ER -